// App-Quantinova.ai

BSH19‐PO‐032 : CIP2A alters energy metabolism in CML cells, thus contributing to TKI resistance

Researchers

Presenter

  • J.A. Austin

Principal Investigators

  • G. Austin

  • M. Glenn

  • K. Dunn

  • L. Scott

  • C. Lucas

  • R. Clark

Medical Centers

  • Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Tuberculosis

Biomarkers

  • AMP-activated protein kinase

  • Breakpoint Cluster Region

  • Cancerous inhibitor of protein phosphatase 2A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved